Molecular Partners AG(US:MOLN)2026-03-12 20:54Financial Performance - Total revenues for 2025 were CHF 0, a decrease from CHF 5.0 million in 2024, primarily due to the conclusion of revenue recognition from the Novartis collaboration agreement[37]. - R&D expenses decreased to CHF 40.2 million in 2025 from CHF 48.6 million in 2024, reflecting a reduction of CHF 8.4 million[35]. - The net cash outflow from operating activities was CHF 51.3 million in 2025, an improvement from CHF 59.2 million in 2024[35]. - The Group generated an operating loss of CHF 58.1 million in 2025, an improvement from a loss of CHF 61.2 million in 2024[41]. - The net loss for 2025 was CHF 61.7 million, compared to a net loss of CHF 54.0 million in 2024[43]. - Total operating expenses for 2025, including depreciation and amortization, were CHF 58.1 million, down from CHF 66.1 million in 2024[35]. - In 2025, total operating expenses decreased by CHF 7.9 million to CHF 58.1 million, with personnel expenses accounting for CHF 34.7 million (60% of total operating expenses) and external research costs totaling CHF 11.2 million (19% of total operating expenses)[39]. - The company expects full-year 2026 operating expenses to be between CHF 45 million and CHF 55 million[12]. - For 2026, the Group expects total operating expenses to be between CHF 45-55 million, including approximately CHF 6 million in non-cash effective costs[53]. Cash and Liquidity - Cash and cash equivalents, including short-term deposits, amounted to CHF 93.1 million as of December 31, 2025, providing a financial runway until 2028[36]. - As of December 31, 2025, cash and cash equivalents decreased by CHF 56.3 million to CHF 93.1 million, representing 91% of total assets[44]. - The Group's liquidity position is strong, with CHF 93.1 million in cash, estimated to fund operations until 2028[56]. Research and Development - The company initiated a Phase 1/2a study of its lead Radio-DARPin candidate MP0712 targeting DLL3 for small cell lung cancer, with recruitment now open[6]. - MP0726, the second Radio-DARPin candidate targeting mesothelin, has been nominated and proof-of-concept data was presented at SNMMI 2025[11]. - The company presented encouraging imaging and dosimetry data for MP0712 at TWC 2026, supporting its clinical development[11]. - The pipeline includes clinical-stage candidates targeting oncology, with a focus on Radio-DARPin Therapy for small cell lung cancer and a tetraspecific T cell engager for acute myeloid leukemia[72]. - The company has initiated a Phase 1/2a trial for MP0712, targeting DLL3 in small cell lung cancer, with initial clinical data expected in 2026[81]. - MP0726, targeting MSLN in ovarian cancer, is progressing towards first-in-human imaging, with preclinical data presented in June 2025[86]. - MP0317 has completed a Phase 1 dose-escalation study, showing tumor-localized CD40 activation and TME remodeling in 46 patients[93]. - MP0533 is currently in a Phase 1/2a trial for relapsed/refractory AML, with data indicating tolerability and improved serum exposure[98]. - The company plans to present preclinical data on Radio-DARPins' suitability with multiple isotopes at the 3rd Global Radiopharmaceuticals Development Summit in March 2026[88]. - The company is evaluating various radionuclides to tailor Radio-DARPin candidates to patient needs, enhancing therapeutic applications[88]. - The Switch-DARPin technology aims to improve the safety and potency of T cell engagers by enabling conditional activation in specific biological contexts[102]. - The company intends to nominate a lead Switch-DARPin candidate for development in H1 2026, with updates expected at the AACR Annual Meeting in April 2026[107]. - Molecular Partners' MP0621 program is designed to enhance the efficacy of hematopoietic stem cell transplantation, with pre-clinical proof-of-mechanism data presented at major conferences[110]. Corporate Governance - The company has established a Quality Management System to ensure compliance with regulations and maintain product quality and patient safety[129]. - The company emphasizes the importance of corporate governance, with detailed responsibilities outlined for each committee[184]. - The organizational rules and powers of the CEO are available for reference, indicating a structured governance framework[185]. - The Board of Directors consists of eight members as of December 31, 2025, and is responsible for the ultimate direction of the company's business[169][171]. - The Board of Directors met two times in person and conducted six telephone conference meetings in 2025[174]. - The Audit and Finance Committee reviews the financial statements and reports from the external auditor prior to their public release[181]. - The company has not reported any changes in the membership of the Board of Directors during 2025[187]. - The Board of Directors consists of non-executive members, with Patrick Amstutz serving as the CEO since the company's inception[187]. Shareholder Information - The company has a market capitalization of CHF 137 million as of December 31, 2025[134]. - Significant shareholders include Mark N. Lampert with 21.54% and Suvretta Capital with 10.62% of voting rights[136]. - The issued share capital of the company amounted to CHF 4,037,464.10, divided into 40,374,641 fully paid registered shares as of December 31, 2025[140]. - The conditional share capital amounted to CHF 363,419, equating to approximately 9% of the existing share capital[148]. - The share capital may be increased by up to CHF 226,087 through the issuance of 2,260,870 fully paid registered shares, representing about 6% of the existing share capital[149][151]. - The company has not issued participation certificates or dividend-right certificates[154]. - The company has not paid dividends since its inception and does not anticipate doing so in the foreseeable future[163]. - Shareholders must be registered in the share register at least six business days prior to the general meeting to be entitled to vote[158]. Employee and Social Responsibility - The company is focusing its ESG efforts on five priority areas, including human capital management and diversity, equity, and inclusion[115]. - The company offers flexible working arrangements and training programs to support employee growth and well-being[118][119]. - The company has waived future royalties from ensovibep in developing regions as part of its corporate social responsibility commitment[127]. - The company has implemented cutting-edge IT systems for data protection and cybersecurity, ensuring high standards of data security[124]. - The board of directors includes seven male directors and one female director, with two members identifying as underrepresented individuals[130].